The treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has expanded substantially in recent years, with multiple targeted and T-cell-mediated therapies recently approved with more in advanced stages of clinical development, providing both opportunities and challenges to personalizing treatment plans. Don’t miss this opportunity to hear leading DLBCL experts examine the latest guidelines and clinical data for current and emerging treatment options for R/R DLBCL, as well as strategies to tailor treatment to patient- and disease-specific factors. Featured in this activity is a concise 2D animation video assessing mechanisms of treatment resistance and novel targets of DLBCL therapies that you can access as part of this Accelerator Hub.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/novel-therapies-dlbcl-current-emerging-approaches-personalized-care
- Start Date: 2024-10-31 05:00:00
- End Date: 2024-10-31 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Pfizer (Any division) - Amount: 45000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all